The lecture systematically reviewed the cutting-edge research of the research group in the past five years. The lecture pointed out that in the context of precision medicine, fluorescence analysis technology based on liquid biopsy is the key to breaking through the clinical "bottleneck" of breast cancer diagnosis and treatment. Focusing on this core, the lecture focused on summarizing three major research progresses: First, innovation in methodology was achieved, and a restricted reaction strategy using the nucleic acid structure as a thermodynamic limiter was proposed, which effectively solved the problem of reduced sensitivity caused by random reactions in detection. The second is to achieve a breakthrough in detection technology and build a tandem multi-level hierarchical detection system, which significantly improves the detection capability of low-abundance and high-specific targets and enhances the selectivity of analysis. The third is to focus on clinical translation and strive to develop and promote clinically available rapid testing technologies through prospective clinical research. The research covers a variety of liquid biopsy markers such as proteins, nucleic acids, and metabolites. Improved detection specificity through modular combination strategy ； The constructed bionic fluorescence detection technology has demonstrated high accuracy in early diagnosis and monitoring of breast cancer in clinical verification.

Based on the platform of inorganic nanomaterials and DNA nanomaterials, the research team focuses on the integration of early diagnostic marker detection and diagnosis and treatment. Through multidisciplinary integration, we finally successfully developed a series of new technologies for early diagnosis and treatment of breast cancer from basic innovation to clinical application, clearly demonstrating the great potential and value of fluorescence analysis technology in promoting precise diagnosis and treatment.